FDA Approves Novocure's Optune Pax: A New Hope for Pancreatic Cancer Patients

Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.